Stay updated on Omalizumab in Multi-Allergen OIT Clinical Trial
Sign up to get notified when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.

Latest updates to the Omalizumab in Multi-Allergen OIT Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a Locations section listing study sites by state (Arkansas, California, Colorado, Georgia, Maryland, Massachusetts, New York, North Carolina, Pennsylvania, Texas) and updated the revision to v3.3.3.SummaryDifference0.7%

- Check53 days agoChange DetectedPublication section updated: added language that publications are provided voluntarily by the person entering information, and the revision label updated to v3.3.2 (replacing the previous phrasing about the study results). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedNotice about lapse in government funding and operating status has been removed; the page no longer provides guidance to check current status on cc.nih.gov or opm.gov.SummaryDifference0.2%

- Check82 days agoChange DetectedTwo screenshots show no substantive changes to the Study Details page; core data remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check104 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference0.5%

Stay in the know with updates to Omalizumab in Multi-Allergen OIT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.